Previous close | 0.0490 |
Open | 0.0540 |
Bid | 0.0500 x N/A |
Ask | 0.0520 x N/A |
Day's range | 0.0500 - 0.0550 |
52-week range | 0.0100 - 0.1750 |
Volume | |
Avg. volume | 3,053,511 |
Market cap | 24.065M |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received clearance from the US Food and Drug Administration (FDA) to market its FebriDx® rapid, point-of-care test in the United States.